Abstract

TBI (traumatic brain injury) is a major cause of death among youth in industrialized societies. Brain damage following traumatic injury is a result of direct and indirect mechanisms; indirect or secondary injury involves the initiation of an acute inflammatory response, including the breakdown of the blood–brain barrier (BBB), brain edema, infiltration of peripheral blood cells, and activation of resident immunocompetent cells, as well as the release of numerous immune mediators such as interleukins and chemotactic factors. TBI can cause changes in molecular signaling and cellular functions and structures, in addition to tissue damage, such as hemorrhage, diffuse axonal damages, and contusions. TBI typically disturbs brain functions such as executive actions, cognitive grade, attention, memory data processing, and language abilities. Animal models have been developed to reproduce the different features of human TBI, better understand its pathophysiology, and discover potential new treatments. For many years, the first approach to manage TBI has been treatment of the injured tissue with interventions designed to reduce the complex secondary-injury cascade. Several studies in the literature have stressed the importance of more closely examining injuries, including endothelial, microglia, astroglia, oligodendroglia, and precursor cells. Significant effort has been invested in developing neuroprotective agents. The aim of this work is to review TBI pathophysiology and existing and potential new therapeutic strategies in the management of inflammatory events and behavioral deficits associated with TBI.

Highlights

  • Traumatic brain injury (TBI) is defined as damage to the brain sustained after the application of external physical force that causes temporary or permanent functional or structural damage to the brain

  • In this review, we describe the current therapeutic strategies and new therapeutic approaches for the treatment of neuroinflammatory phenomena and TBI symptom management

  • Excitotoxicity is a process characterized by increased levels of neurotransmitters and glutamate in the synaptic space that stimulate the surrounding nerve cells’ N-methyl-d-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors [10]

Read more

Summary

Introduction

Traumatic brain injury (TBI) is defined as damage to the brain sustained after the application of external physical force that causes temporary or permanent functional or structural damage to the brain. In this method, treatment is started as soon as possible after injury. Treatment is started as soon as possible after injury Another methodology, more studied in clinical trials of mTBI patients, is one of targeting symptoms such as vestibular/oculomotor disturbances, headache, sleep illnesses, post-traumatic stress disorder (PTSD), cognitive dysfunction, or others [3,5]. More studied in clinical trials of mTBI patients, is one of targeting symptoms such as vestibular/oculomotor disturbances, headache, sleep illnesses, post-traumatic stress disorder (PTSD), cognitive dysfunction, or others [3,5] Based on these findings, in this review, we describe the current therapeutic strategies and new therapeutic approaches for the treatment of neuroinflammatory phenomena and TBI symptom management

The Pathophysiology of TBI
TBI and Neurotoxicity
TBI and Oxidative Stress
Biomarkers in TBI
Review of Existing Drug Interventions
Clinical Trials of Drugs with Anti-Inflammatory Effect
New Therapeutic Strategies
Biologics
10. Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call